56578-38-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluorocinnamaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs due to its unique chemical properties and reactivity.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Fluorocinnamaldehyde serves as an important intermediate, playing a crucial role in the production of pesticides and other agrochemicals to enhance crop protection and yield.
Used in Organic Compounds Synthesis:
3-Fluorocinnamaldehyde is used as a precursor in the synthesis of organic compounds such as dyes and fragrances, adding to the diversity of products in the chemical industry.
Used in Research and Development:
3-Fluorocinnamaldehyde is utilized in research for its potential pharmacological properties, including its investigation as an anticancer and anti-inflammatory agent, which could lead to advancements in medical treatments.
Used in Fragrance Industry:
In the fragrance industry, 3-Fluorocinnamaldehyde is used as a component in creating various scents, capitalizing on its strong, sweet, floral odor to enhance perfumes and other scented products.

InChI:InChI=1/C9H7FO/c10-9-5-1-3-8(7-9)4-2-6-11/h1-7H/b4-2+

Upstream product

• 3054-95-3 acrylaldehyde diethyl acetal 
• 1121-86-4 1-Fluoro-3-iodobenzene 
• 1073-06-9 3-fluorobromobenzene 
• 125872-67-5 (E)-3-(3-fluorophenyl)prop-2-en-1-ol 
• 197239-54-6 3-(3-fluorophenyl)prop-2-yn-1-ol 
• 107-18-6 allyl alcohol 
• 124-38-9 carbon dioxide 
• 2561-17-3 1-ethynyl-3-fluoro-benzene 
• 201230-82-2 carbon monoxide 
• 26905-44-2 3-(3-fluorophenyl)-2-propen-1-ol 
• 456-48-4 3-Fluorobenzaldehyde 
• 2136-75-6 (triphenylphosphoranylidene)acetaldehyde 
• 74325-03-4 methyl (E)-m-fluorocinnamate 
• 1446099-77-9 (E)-3-(dimethyl(phenyl)silyl)-1-(3-fluorophenyl)prop-2-en-1-ol 

Downstream Products

• 1000682-29-0 C₁₂H₁₀FN₃O₂ 
• 1065509-93-4 3-(3-fluorophenyl)-4-nitrobutyraldehyde 
• 1073495-61-0 (1R)-9-fluoro-1-[(4-{[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one 
• 1361214-42-7 C₂₅H₂₉FN₂O₃ 
• 1361214-45-0 (R)-tert-butyl 3-((2R,3S)-2-((E)-3-fluorostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-4-(((R)-1-phenylethyl)amino)butanoate 
• 1361214-48-3 (R)-3-((2R,3S)-2-((E)-3-fluorostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-4-(((R)-1-phenylethyl)amino)butanoic acid 
• 1361214-50-7 (R)-4-([1,4'-bipiperidin]-1'-yl)-2-((2R,3S)-2-((E)-3-fluorostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-N-((R)-1-phenylethyl)butanamide 
• 98451-41-3 (E)-1-(buta-1,3-dien-1-yl)-3-fluorobenzene 
• 1222468-69-0 (S)-3-(3-fluoro-phenyl)-3-(1,1,3,3-tetraoxo-2,3-dihydro-1H-1λ(6),3λ(6)-benzo[1,3]dithiol-2-yl)-propionaldehyde 
• 1320256-66-3 (E)-N-(tert-butyl)-4-(3-fluorophenyl)-2-oxobut-3-enamide 
• 1403338-07-7 (2'S,3'R)-tert-butyl 3'-(3-fluorophenyl)-1-methyl-2,5'-dioxospiro[indoline-3,2'-pyrrolidine]-1'-carboxylate 

Relevant academic research and scientific papers

Selective Rhodium-Catalyzed Hydroformylation of Terminal Arylalkynes and Conjugated Enynes to (Poly)enals Enabled by a π-Acceptor Biphosphoramidite Ligand

The hydroformylation of terminal arylalkynes and enynes offers a straightforward synthetic route to the valuable (poly)enals. However, the hydroformylation of terminal alkynes has remained a long-standing challenge. Herein, an efficient and selective Rh-catalyzed hydroformylation of terminal arylalkynes and conjugated enynes has been achieved by using a new stable biphosphoramidite ligand with strong π-acceptor capacity, which affords various important E-(poly)enals in good yields with excellent chemo- and regioselectivity at low temperatures and low syngas pressures.

Method for preparing olefine aldehyde by catalyzing terminal alkyne or terminal conjugated eneyne and diphosphine ligand used in method

The invention discloses a method for preparing olefine aldehyde by catalyzing terminal alkyne or terminal conjugated eneyne and a diphosphine ligand used in the method. According to the invention, indole-substituted phosphoramidite diphosphine ligand which is stable in air and insensitive to light is synthesized by utilizing a continuous one-pot method, and the indole-substituted phosphoramidite diphosphine ligand and a rhodium catalyst are used for jointly catalyzing to successfully achieve a hydroformylation reaction of aromatic terminal alkyne and terminal conjugated eneyne under the condition of synthesis gas for the first time, so that an olefine aldehyde structure compound can be rapidly and massively prepared, and particularly, a polyolefine aldehyde structure compound which is more difficult to synthesize in the prior art can be easily prepared and synthesized, and a novel method is provided for synthesis and modification of drug molecules, intermediates and chemical products.

Regioselective Silylations of Propargyl and Allyl Pivalates through Ca-Promoted Reductive C(sp3)-O Bond Cleavage

A practical protocol for the regioselective preparation of 3-phenylpropargylsilanes and 3-phenylallylsilanes in yields of 36-77 and 48-86%, respectively, from readily accessible 3-phenylpropargyl and 1-phenylallyl pivalates was developed through reductive C(sp3)-O bond cleavage. This method represents the first example of the direct application of vastly abundant calcium granules to a reductive coupling reaction. A broad range of propargylsilanes and allylsilanes are simply prepared using easy-to-handle pivalates and chlorotrimethylsilane under mild catalyst-free and additive-free conditions.

Potent Inhibition of Nicotinamide N-Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics

Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (vitamin B3) to generate 1-methylnicotinamide (MNA). NNMT overexpression has been linked to a variety of diseases, most prominently human cancers, indicating its potential as a therapeutic target. The development of small-molecule NNMT inhibitors has gained interest in recent years, with the most potent inhibitors sharing structural features based on elements of the nicotinamide substrate and the S-adenosyl-l-methionine (SAM) cofactor. We here report the development of new bisubstrate inhibitors that include electron-deficient aromatic groups to mimic the nicotinamide moiety. In addition, a trans-alkene linker was found to be optimal for connecting the substrate and cofactor mimics in these inhibitors. The most potent NNMT inhibitor identified exhibits an IC50 value of 3.7 nM, placing it among the most active NNMT inhibitors reported to date. Complementary analytical techniques, modeling studies, and cell-based assays provide insights into the binding mode, affinity, and selectivity of these inhibitors.

Highly Regio- A nd Enantioselective Hydrogenation of Conjugated α-Substituted Dienoic Acids

Highly regio- A nd enantioselective hydrogenation of conjugated α-substituted dienoic acids was realized for the first time using Trifer-Rh complex, providing a straightforward method for the synthesis of chiral α-substituted ?,?′-unsaturated acids. DFT calculations revealed N+H-O hydrogen bonding interaction is formed to stabilize the transition state and the coordination of 4,5-double bond to Rh(III) center would facilitate the reductive elimination process. This hydrogenation provided a gram-scale synthesis of the precursor of sacubitril.

Enantioenriched Methylene-Bridged Benzazocanes Synthesis by Organocatalytic and Superacid Activations

Achieving in a straightforward way the synthesis of enantioenriched elaborated three-dimensional molecules related to bioactive natural products remains a long-standing quest in organic synthesis. Enantioselective organocatalysis potentially offers a uniq

Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections

Inhibition of S. aureus diapophytoene desaturase (CrtN) could serve as an alternative approach for addressing the tricky antibiotic resistance by blocking the biosynthesis of carotenoid pigment which shields the bacterium from host oxidant killing. In this study, we designed and synthesized 44 derivatives with piperonyl scaffold targeting CrtN and the structure-activity relationships (SARs) were examined extensively to bring out the discovery of 21b with potent efficacy and better hERG safety profile compared to the first class CrtN inhibitor benzocycloalkane derivative 2. Except the excellent pigment inhibitory activity against wild-type S. aureus, 21b also showed excellent pigment inhibition against four pigmented MRSA strains. In addition, H2O2 killing and human whole blood killing assays proved 21b could sensitize S. aureus to be killed under oxidative stress conditions. Notably, the murine study in vivo validated the efficacy of 21b against pigmented S. aureus Newman, vancomycin-intermediate S. aureus Mu50 and linezolid-resistant S. aureus NRS271.

Synthesis of α-pyrones by catalytic oxidative coupling of terminal alkynes and carbon dioxide

The use of the complex [(dippe)Ni(μ-H)]2(1) as a catalyst precursor (10?mol%) in the presence of a variety of terminal alkynes and CO2allowed the production of substituted α–pyrones. This reaction occurs using relatively mild conditions (50?°C, 150 psi of CO2) with good to modest yields, depending on the nature of the substituents in the corresponding alkyne. The produced α–pyrones were characterized by different analytical methods and spectroscopic techniques.

Tubulin inhibitor

The invention provides a novel tubulin inhibitor and an application thereof. The novel tubulin inhibitor is a series of substituted heterocyclic skeleton-based compounds with colchicine binding sites in tubulins as targets. The compounds have the following structure as shown in the specification, wherein the formula is as shown in the specification; n independently represents an integer of 0-5 under the condition that n is less than or equal to 5; A represents a monosubstituted or polysubstituted group; and the group is selected from H, C1-C20 acylamino, C1-C20 acyloxy, C1-C20 alkanoyl, C1-C20 alkoxycarbonyl, C1-C20 alkoxy, C1-C20 alkylamino, C1-C20 alkylcarboxy amino, aroyl, arylalkanoyl, carboxyl, cyano, halogen, hydroxyl, nitro and methylthienyl.

Tubulin inhibitor

The invention provides a novel tubulin inhibitor and an application thereof. The novel tubulin inhibitor is a series of substituted heterocyclic skeleton-based compounds with colchicine binding sites in tubulins as targets. The compounds have the following structure as shown in the specification, wherein the formula is as shown in the specification; n independently represents an integer of 0-5 under the condition that n is less than or equal to 5; A represents a monosubstituted or polysubstituted group; and the group is selected from H, C1-C20 acylamino, C1-C20 acyloxy, C1-C20 alkanoyl, C1-C20 alkoxycarbonyl, C1-C20 alkoxy, C1-C20 alkylamino, C1-C20 alkylcarboxy amino, aroyl, arylalkanoyl, carboxyl, cyano, halogen, hydroxyl, nitro and methylthienyl.